283 related articles for article (PubMed ID: 20226822)
41. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
42. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
43. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles.
Vandenbroucke RE; Lentacker I; Demeester J; De Smedt SC; Sanders NN
J Control Release; 2008 Mar; 126(3):265-73. PubMed ID: 18237813
[TBL] [Abstract][Full Text] [Related]
44. Targeted delivery of an anti-cancer agent via steroid coupled liposomes.
Mishra PK; Gulbake A; Jain A; Vyas SP; Jain SK
Drug Deliv; 2009 Nov; 16(8):437-47. PubMed ID: 19839788
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
46. Efficient intracellular siRNA delivery strategy through rapid and simple two steps mixing involving noncovalent post-PEGylation.
Kong WH; Sung DK; Shim YH; Bae KH; Dubois P; Park TG; Kim JH; Seo SW
J Control Release; 2009 Sep; 138(2):141-7. PubMed ID: 19426771
[TBL] [Abstract][Full Text] [Related]
47. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
48. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
49. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA.
Han SE; Kang H; Shim GY; Suh MS; Kim SJ; Kim JS; Oh YK
Int J Pharm; 2008 Apr; 353(1-2):260-9. PubMed ID: 18178348
[TBL] [Abstract][Full Text] [Related]
50. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J
Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128
[TBL] [Abstract][Full Text] [Related]
51. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome.
Watanabe T; Umehara T; Yasui F; Nakagawa S; Yano J; Ohgi T; Sonoke S; Satoh K; Inoue K; Yoshiba M; Kohara M
J Hepatol; 2007 Dec; 47(6):744-50. PubMed ID: 17822798
[TBL] [Abstract][Full Text] [Related]
52. Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles.
Musacchio T; Vaze O; D'Souza G; Torchilin VP
Bioconjug Chem; 2010 Aug; 21(8):1530-6. PubMed ID: 20669936
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
54. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
55. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
56. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
[TBL] [Abstract][Full Text] [Related]
57. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes.
Schlegel A; Largeau C; Bigey P; Bessodes M; Lebozec K; Scherman D; Escriou V
J Control Release; 2011 Jun; 152(3):393-401. PubMed ID: 21497175
[TBL] [Abstract][Full Text] [Related]
58. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression.
Arima H; Tsutsumi T; Yoshimatsu A; Ikeda H; Motoyama K; Higashi T; Hirayama F; Uekama K
Eur J Pharm Sci; 2011 Oct; 44(3):375-84. PubMed ID: 21896329
[TBL] [Abstract][Full Text] [Related]
59. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
60. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
Shim G; Han SE; Yu YH; Lee S; Lee HY; Kim K; Kwon IC; Park TG; Kim YB; Choi YS; Kim CW; Oh YK
J Control Release; 2011 Oct; 155(1):60-6. PubMed ID: 20971142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
